Bausch + Lomb Corp banner

Bausch + Lomb Corp
NYSE:BLCO

Watchlist Manager
Bausch + Lomb Corp Logo
Bausch + Lomb Corp
NYSE:BLCO
Watchlist
Price: 16.05 USD 0.06% Market Closed
Market Cap: $5.7B

EV/EBITDA

16.9
Current
1%
More Expensive
vs 3-y average of 16.8

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
16.9
=
Enterprise Value
$11B
/
EBITDA
$609m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
16.9
=
Enterprise Value
$11B
/
EBITDA
$609m

Valuation Scenarios

Bausch + Lomb Corp is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (16.8), the stock would be worth $15.92 (1% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-40%
Maximum Upside
No Upside Scenarios
Average Downside
16%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 16.9 $16.05
0%
3-Year Average 16.8 $15.92
-1%
5-Year Average 16.4 $15.56
-3%
Industry Average 13.4 $12.7
-21%
Country Average 10.2 $9.63
-40%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$11B
/
Jan 2026
$609m
=
16.9
Current
$11B
/
Dec 2026
$1B
=
10.6
Forward
$11B
/
Dec 2027
$1.2B
=
9.4
Forward
$11B
/
Dec 2028
$1.3B
=
8.4
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CA
Bausch + Lomb Corp
NYSE:BLCO
5.7B USD 16.9 -15.7
US
Medline Inc
NASDAQ:MDLN
62B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 28.1 38.7
CH
Alcon AG
SIX:ALC
30.1B CHF 14.5 37.7
DK
Coloplast A/S
CSE:COLO B
96.5B DKK 12.7 24
US
Align Technology Inc
NASDAQ:ALGN
14B USD 14.9 34.1
UK
ConvaTec Group PLC
LSE:CTEC
4.5B GBP 11.9 34.3
KR
HLB Inc
KOSDAQ:028300
8T KRW -81.4 -36.4
JP
Asahi Intecc Co Ltd
TSE:7747
868.9B JPY 23.2 49.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 14.7 22.9
CN
Intco Medical Technology Co Ltd
SZSE:300677
36.4B CNY 31.5 21.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Bausch + Lomb Corp
NYSE:BLCO
Average EV/EBITDA: 18.7
16.9
29%
0.6
US
M
Medline Inc
NASDAQ:MDLN
Not Available
9%
N/A
JP
Hoya Corp
TSE:7741
28.1
13%
2.2
CH
Alcon AG
SIX:ALC
14.5
9%
1.6
DK
Coloplast A/S
CSE:COLO B
12.7
6%
2.1
US
Align Technology Inc
NASDAQ:ALGN
14.9
14%
1.1
UK
ConvaTec Group PLC
LSE:CTEC
11.9
11%
1.1
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -81.4 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
23.2
13%
1.8
US
Lantheus Holdings Inc
NASDAQ:LNTH
14.7
23%
0.6
CN
Intco Medical Technology Co Ltd
SZSE:300677
31.5
51%
0.6
P/E Multiple
Earnings Growth PEG
CA
Bausch + Lomb Corp
NYSE:BLCO
Average P/E: 32.8
Negative Multiple: -15.7
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.7
15%
2.6
CH
Alcon AG
SIX:ALC
37.7
32%
1.2
DK
Coloplast A/S
CSE:COLO B
24
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
34.1
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
34.3
41%
0.8
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.4 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
49.1
40%
1.2
US
Lantheus Holdings Inc
NASDAQ:LNTH
22.9
30%
0.8
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.4
12%
1.8

Market Distribution

Higher than 77% of companies in Canada
Percentile
77th
Based on 2 002 companies
77th percentile
16.9
Low
0 — 7
Typical Range
7 — 14.5
High
14.5 —
Distribution Statistics
Canada
Min 0
30th Percentile 7
Median 10.2
70th Percentile 14.5
Max 13 731.1

Bausch + Lomb Corp
Glance View

Market Cap
5.7B USD
Industry
Health Care

Founded in 1853, Bausch + Lomb Corp. began as a small optical goods store in Rochester, New York, eventually blossoming into a multinational eye health business. Over its long history, the company has established itself as a cornerstone in the realm of vision care, leveraging its deep expertise to innovate and expand its product offerings. Today, Bausch + Lomb operates through three primary business segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. In the Vision Care segment, it provides contact lenses, lens care products, and other related items, making it a trusted choice for consumers around the globe. The Ophthalmic Pharmaceuticals division addresses a broad spectrum of eye health needs, producing prescription and over-the-counter pharmaceuticals that target various eye conditions. Meanwhile, the Surgical segment offers a suite of ophthalmic surgical devices, designed for procedures ranging from cataract extraction to vitreoretinal surgery. Bausch + Lomb generates revenue through a mix of consumer products and medical equipment. Their extensive contact lens product line caters to diverse needs – from daily disposables to specialized lenses for specific eye conditions, thereby capturing a significant portion of the eye care market. The company's pharmaceuticals and surgical tools not only complement its vision care products but also tap into the lucrative medical market, providing solutions for both medical professionals and their patients. By maintaining a robust portfolio that spans consumer goods and professional-grade equipment, Bausch + Lomb effectively positions itself as both a retail and medical partner, ensuring steady revenue streams from a global customer base. With a blend of research-driven innovation and strategic market positioning, Bausch + Lomb continues to cement its legacy as a leader in eye health.

BLCO Intrinsic Value
23.81 USD
Undervaluation 33%
Intrinsic Value
Price $16.05
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett